诚意药业: 浙江诚意药业股份有限公司股票交易异常波动公告

Core Viewpoint - Zhejiang Chengyi Pharmaceutical Co., Ltd. experienced a significant stock price fluctuation, with a cumulative closing price increase of 20% over three consecutive trading days, triggering an abnormal trading situation as per Shanghai Stock Exchange regulations [1][2]. Group 1: Stock Trading Abnormality - The company's stock price increased by a cumulative 20% on July 11, July 14, and July 15, 2025, which is classified as an abnormal trading situation according to the Shanghai Stock Exchange rules [1][2]. - The company conducted a self-examination and confirmed that there are no undisclosed significant matters affecting the stock price, including major asset restructuring or significant transactions [2][3]. Group 2: Company Operations and Market Conditions - The company's production and operational activities are normal, with no significant changes in market environment or industry policies, and no substantial fluctuations in production costs or sales [2]. - There have been no media reports or market rumors that require clarification, and no other significant events that could impact the stock price have been identified [2]. Group 3: Board of Directors' Statement - The board of directors confirmed that there are no undisclosed matters that should be reported according to the Shanghai Stock Exchange listing rules, and previous disclosures do not require correction or supplementation [3].